Trial Profile
A study of M834 a biosimilar of Abatacept
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 25 Aug 2016
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Autoimmune disorders; Inflammation
- Focus Adverse reactions
- 25 Aug 2016 New trial record